openPR Logo
Press release

Transthyretin Amyloidosis Treatment Market Opportunities And Strategies 2024-2033 - Size, Growth Analysis, Outlook, Overview

09-26-2024 06:06 AM CET | Health & Medicine

Press release from: The Business research company

Transthyretin Amyloidosis Treatment Market Opportunities

Transthyretin Amyloidosis Treatment Market Opportunities

The Business Research Company recently released a comprehensive report on the Global Transthyretin Amyloidosis Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

According to The Business Research Company's, The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..

The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $7.42 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment.. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines..

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Market Drivers and Trends:

Rising investments in research and development are expected to propel the growth of the transthyretin amyloidosis treatment market going forward. Research and development (R&D) investments include financial resources allocated to activities aimed at advancing scientific knowledge, developing new technologies, creating innovative products, and improving existing processes. Increased funding in research and development enables the discovery and development of innovative treatment approaches for transthyretin amyloidosis, including novel drugs, gene therapies, and precision medicine techniques, offering patients more effective and targeted treatment options. For instance, in December 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company engaged in the development of Vutrisiran, a treatment of ATTR amyloidosis, increased its research and development investment to $883,015 in 2022 from $792,156 in 2021, reflecting a growth of 11.49%. Therefore, the rising investment in research and development will drive the growth of the transthyretin amyloidosis treatment market.

Major companies in the transthyretin amyloidosis treatment market focus on developing innovative and specialized treatments, such as orphan drugs, to enhance patient outcomes and expand treatment options. Eplontersen is an orphan drug specifically designed to treat transthyretin amyloidosis condition, often receiving regulatory benefits to support its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, received The Food and Drug Administration (FDA) approval of a new drug application for Eplontersen, an experimental orphan drug intended for the treatment of familial transthyretin-mediated amyloid, leading to progressive polyneuropathy. Eplontersen is a pharmaceutical agent developed to mitigate the synthesis of transthyretin (TTR) protein to address both the hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA granted Eplontersen orphan drug designation in 2022.`

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

Major Key Players of the Market:

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc, Abbvie Inc, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, GSK Plc, Novo Nordisk A/S, Merck & Co. Inc, Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc, Acrotech Biopharma Inc, Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc, Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

Transthyretin Amyloidosis Treatment Market 2024 Key Insights:

• The transthyretin amyloidosis treatment market is expected to grow to $7.42 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%.
• Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market
• Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment
• North America was the largest region in the transthyretin amyloidosis treatment market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13129&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Transthyretin Amyloidosis Treatment Market Opportunities And Strategies 2024-2033 - Size, Growth Analysis, Outlook, Overview here

News-ID: 3668170 • Views:

More Releases from The Business research company

Surgical Meshes Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth
Surgical Meshes Market Landscape to 2034: Key Forces Shaping the Next Decade of …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Surgical Meshes Market Size By 2025? In the past few years, the market size of surgical meshes has seen significant growth. It is projected to expand from $2.03 billion in 2024 to $2.18 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 7.3%.
Rehabilitation Equipment Market Poised to Hit $23.97 Billion by 2029 with Accelerating Growth Trends
Rehabilitation Equipment Market Poised to Hit $23.97 Billion by 2029 with Accele …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Rehabilitation Equipment Market Size Growth Forecast: What to Expect by 2025? In recent times, there has been a significant growth in the size of the rehabilitation equipment market. Projected to increase from $17.36 billion in 2024, it is expected to reach $18.49 billion in 2025, with a compound annual
Future of the Pediatric Neurology Device Market: Strategic Analysis and Forecast to 2034
Future of the Pediatric Neurology Device Market: Strategic Analysis and Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Pediatric Neurology Device Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for pediatric neurology devices has seen significant expansion in recent years, climbing from $2.5 billion in 2024 to an anticipated $2.65 billion in 2025, reflecting a compound annual growth rate (CAGR)
Key Trends Influencing the Growth of the Orthokeratology Lens Market in 2025: Innovative Products Boosting Profitability in the Orthokeratology Lens Market
Key Trends Influencing the Growth of the Orthokeratology Lens Market in 2025: In …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Orthokeratology Lens Market Through 2025? The market for orthokeratology lenses has seen a significant increase in size over recent years. It's projected to expand from $2.56 billion in 2024 to $2.75 billion in 2025, with a compound annual growth rate (CAGR) of

All 5 Releases


More Releases for Transthyretin

Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period? The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market? The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress
Transthyretin Amyloid Cardiomyopathy Market Statistical Forecast, Trade Analysis …
DataM Intelligence has published a new research report on "Transthyretin Amyloid Cardiomyopathy Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.. The transthyretin amyloidosis treatment market size is
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals
Anti-Transthyretin Global Market Research Report 2025
Anti-Transthyretin Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/anti-transthyretin-market/80994 The report firstly introduced the Anti-Transthyretin basics: definitions, classifications, applications and market overview;